Clinical Trial Update: Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the efficacy and safety of fixed doses of BMS 820836 in patients with treatment-resistant major depression. The study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BMS-820836

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Depression | Phase 2 | Status: COMPLETED